Multidrug-resistant Acinetobacter baumannii bacteraemia:: clinical features, antimicrobial therapy and outcome
Multidrug-resistant Acinetobacter baumannii bacteraemia:: clinical features, antimicrobial therapy and outcome
复制标题
DOI：
10.1111/j.1469-0691.2006.01601.x
复制
发表时间：
2007-02-01
影响因子：
14.2
通讯作者：
Hsueh, P. -R.
中科院分区：
文献类型：
--
作者：
Kuo, L. -C.;Lai, C. -C.;Hsueh, P. -R.
鲍曼不动杆菌引起的医院感染近年来有所增加。自1999年以来，台湾地区已发现多药耐药鲍曼不动杆菌(MDRAB)分离株。对2003年1月至2005年2月收治的55例MDRAb菌血症感染患者的临床资料进行回顾性分析。总的30天死亡率为49%。80%的患者发现了入口，最常累及的是呼吸道。在开出的不同抗菌药物方案中，碳青霉烯类和氨苄西林-舒巴坦联合用药比碳青霉烯和阿米卡星联合用药或单独使用碳青霉烯类药物效果更好。
Nosocomial infections caused by Acinetobacter baumannii have increased in recent years. Isolates of multidrug-resistant A. baumannii (MDRAB) have been recovered in Taiwan since 1999. The characteristics of 55 patients with MDRAB bacteraemia infections occurring between January 2003 and February 2005 were analysed retrospectively. The overall 30-day mortality rate was 49%. The portal of entry was identified in 80% of patients, with the respiratory tract being implicated most frequently. Among the different antimicrobial regimens prescribed, the combination of a carbapenem and ampicillin-sulbactam was associated with a better outcome than the combination of a carbapenem and amikacin, or a carbapenem alone.